Halozyme Therapeutics HALO Acquired in-process research and development
Acquired in-process research and development at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff.
The official record: Halozyme Therapeutics’s 10-K, filed February 17, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's acquired in-process research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Halozyme Therapeutics's acquired in-process research and development?
- Halozyme Therapeutics (HALO) reported acquired in-process research and development of $71.22M in Q4 2025.
- What does acquired in-process research and development mean?
- Represents the cash outflow associated with acquiring research and development projects that have not yet reached technological feasibility. This is a critical indicator of a company's external innovation strategy and inorganic growth pipeline. It reflects the capital intensity of maintaining a competitive R&D portfolio in high-tech or life science sectors.